
|Videos|January 19, 2016
- NSCLC (Issue 10)
- Volume 10
- Issue 10
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Author(s)Renato G. Martins, MD, MPH
​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non
Advertisement
Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in nonsmall cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI
5






























